Research programme: nicotinic receptor agonists - Pfizer
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA
- 25 Mar 2010 Preclinical trials in Schizophrenia in USA (unspecified route)